Genetic factors underlying tacrolimus intolerance after liver transplantation

Yuan Liu1, Rui Wang2,3†, Peizhen Wen2,3†, Wenbin An2,3†, Jinxin Zheng4, Tao Zhang5, Pengshan Zhang1, Haoyu Wang1, Fan Zou1, Hui Pan1*, Junwei Fan1* and Zhihai Peng1,2,3*

1Department of General Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Department of General Surgery, Xiang’an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China, 3Organ Transplantation Institute of Xiamen University, Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, Xiamen, China, 4Department of Nephrology, Ruijin Hospital, Institute of Nephrology, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 5Department of Organ Transplantation, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Background: Tacrolimus (FK506) is the cornerstone of immunosuppression after liver transplantation (LT), however, clinically, switching from FK506 to cyclosporine (SFTC) is common in LT patients with tacrolimus intolerance. The aim of this study was to investigate the genetic risk of patients with tacrolimus intolerance.

Methods: A total of 114 LT patients were enrolled in this retrospective study. SNPs were genotyped using Infinium Human Exome-12 v1.2 BeadChip, and genome-wide gene expression levels were profiled using Agilent G4112F array.

Results: SFTC was a potential risk factor of dyslipidemia (OR=4.774 [1.122-20.311], \( p = 0.034 \)) and insulin resistance (IR) (OR=6.25 [1.451-26.916], \( p = 0.014 \)), but did not affect the survival of LT patients. Differential expression analysis showed donor CYP3A5, CYP2C9, CFTR, and GSTP1, four important pharmacogenetic genes were significantly up-regulated in the tacrolimus intolerance group. Twelve SNPs of these four genes were screened to investigate the effects on tacrolimus intolerance. Regression analysis showed donor rs4646450 (OR=3.23 [1.22-8.60] per each A allele, \( p = 0.01 \)), donor rs6977165 (OR=6.44 [1.09-37.87] per each C allele, \( p = 0.02 \)), and donor rs776746 (OR=3.31 [1.25-8.81] per each A allele, \( p = 0.01 \)) were independent risk factors of tacrolimus intolerance.

Conclusions: These results suggested that SFTC was a potential risk factor for dyslipidemia and IR after LT. Besides, rs4646450, rs6977165, and rs776746 of CYP3A5 might be the underlying genetic risks of tacrolimus intolerance. This might help transplant surgeons make earlier clinical decisions about the use of immunosuppression.

KEYWORDS
CYP3A5, liver transplantation, tacrolimus intolerance, tacrolimus, insulin resistance
Introduction

With the success of liver transplantation (LT) operation and the use of immunosuppression, the long-term survival of recipients may be limited by metabolic syndrome (1, 2). Metabolic syndrome after transplant mainly consists of diabetes, dyslipidemia, hypertension, and obesity, the core role is insulin resistance (1, 3). To some extent, we believe that more and more metabolic syndrome incidence is because of immunosuppression, especially tacrolimus (FK506) using, which has a narrow therapeutic index and wide interindividual pharmacokinetic variability, which easily causes acute rejection and toxicity (4–6).

Interestingly, we note that some recipients of rapid tacrolimus metabolism must be switched to another immunosuppressive regiments for both economic and safety reasons. Hence, we wonder about the genetic factors behind switching from tacrolimus to cyclosporine (SFTC), as well as the influence of SFTC on prognosis. In this study, we integrate the multi-omics data of our transplant recipient with exome chip and transcriptome data to identify the reason for patients’ intolerance to tacrolimus and achieve individualized medicine.

Materials and methods

Patients

A total of 114 patients who underwent orthotopic liver transplantation between Jan 2015 and Dec 2017 at the First People’s Hospital, affiliated to Shanghai Jiao Tong University School of Medicine, were enrolled in our study. All of them were Han Chinese and received tacrolimus-based immunosuppressive regimens. Nine patients in our study cohort experienced SFTC and One hundred five patients did not experience SFTC (NSFTC). Patients with fasting glucose of more than 110 mg/dl or 6.11 mmol/L were deemed as
candidates for insulin resistance according to the definition of metabolic syndrome. (7)

Ethics statement

Liver transplants are derived from donations after cardiac death (DCD). Does not contain the donated liver obtained from the executed prisoners. The study was approved by the Ethics Committee of Shanghai First Hospital affiliated with Shanghai Jiao Tong University. These methods are based on the Helsinki Declaration and its subsequent amendments or similar ethical standards.

Data hoarding

The pharmacological parameters of tacrolimus include daily dose and drug blood trough concentration. Blood samples for tacrolimus monitoring were collected before morning administration. Blood trough concentration of tacrolimus was detected by the Pro-TracTMII tacrolimus ELISA kit (Diasorin, Stillwater, MN, USA) with a microparticle enzyme immunoassay (ELx 800NB analyzer, BioTek, Winoski, VT, USA). The results of which were then recorded and the tacrolimus trough blood concentration/weight-adjusted-dose ratios (CDR, (ng/ml)/(mg/kg)) in the different periods were calculated.

Gene expression data

Gene expression microarray data used for differential expression analysis has been described in our previous study (8). The expression data of the four samples were evaluated for array intensity distributions (box plots). The expression intensity values were log2 transformed. Further analysis was performed using the R package ‘limma’. The very important pharmacogenetic (VIP) genes (n = 63) were obtained from the Pharmacogenomics Knowledgebase (http://www.PharmGKB.org).

Genomic DNA isolation and Genotyping

The genomic DNA of the donor was extracted from liver tissues (stored at -80°C) using AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany). The genotypes of all samples were determined by Infinium Human Exome-12 v1.2 BeadChip (EXON chip) containing 333,445 exon variations. The CYP3A5 genotype was selected from the Drug Metabolizing Enzymes and Transporters (DMET) chip (9). The recipients analyzed with propensity score matching (PSM) did not have dyslipidemia and insulin resistance before LT, and then some recipients developed dyslipidemia and insulin resistance, and some did not after LT.

Statistical analysis

The SFTC and NSFTC samples used in the expression analysis were selected based on the results of the PSM, eliminating interference due to age, gender, and primary disease. Tacrolimus CDRs were normalized by logarithmic transformation (logCDR). Patients’ survival was calculated with Kaplan-Meier survival curves and compared using the log-rank test. The effects of immunosuppression regimen conversion on postoperative complications were evaluated by logistic regression analysis. Genotype data analysis and quality control were performed by using PLINK software (10). Groups were compared using the Wilcoxon-Mann-Whitney test. All statistical analyses were performed using statistical software R (version 3.5.2). All statistical tests were the two-sided test, and p < 0.05 was considered statistically significant.

Results

Effects of SFTC on survival and prognosis of patients after LT

There were 95 males and 19 females with a mean age of 47.4 ± 9.0 years in our study, the other detailed clinical information is in Table 1. Among these, nine patients experienced SFTC. As Figures 1A-D shows, SFTC was associated with the incidence of insulin resistance (IR) (p = 0.02), as well as might correlated with the incidence of dyslipidemia (p = 0.056), acute rejection (p = 0.171), and hypertension (p = 0.351) after LT. Besides, the forest plot showed that SFTC increased the incidence of IR (p = 0.056), acute rejection (p = 0.171), and dyslipidemia (p = 0.034, OR=4.774 [1.122-20.311]) (Figure 1E). However, there is no statistically significant difference in patient survival between the SFTC group and NSFTC group (p = 0.31, Figure S1). The associations between post-transplant complications and survival are shown in Figure S2.

Identification of genes influencing the SFTC process

Gene expression analysis was conducted using donor liver transcriptome data between the SFTC group and NSFTC group after PSM. The results identified 675 and 596 transcripts expression levels significantly up-regulated and down-regulated, respectively (Figure 2A). To identify genes involved in tacrolimus intolerance, we only focused on those significant genes involved in the metabolism of or response to one or several
TABLE 1 Characteristics of patients enrolled in this study.

| Recipient                          | N = 114 |
|------------------------------------|---------|
| Age (years) (mean ± SD)            | 47.4 ± 9.0 |
| Gender, male/female (n)            | 95/19   |
| Child-Pugh score (mean ± SD)       | 7.1 ± 2.1 |
| MELD score (mean ± SD)             | 11.8 ± 5.6 |
| Tacrolimus logCDR, median (IQR)    |         |
| Week 1                             | 5.5 (5.0-6.1) |
| Week 2                             | 4.9 (5.0-5.3) |
| Week 3                             | 4.7 (4.3-5.2) |
| Week 4                             | 4.8 (4.4-5.3) |
| Post-transplant complications (n)  |         |
| Acute rejection                    | 24      |
| New-onset hypertension             | 19      |
| New-onset dyslipidemia             | 37      |
| Insulin resistance                 | 30      |

Categorical variables are shown as n and continuous variables that are displayed as mean ± standard deviation or median (IQR). IQR, interquartile range. logCDR, logarithmically transformed trough blood concentration/weight-adjusted-dose ratios. The threshold of insulin resistance in the definition of metabolic syndrome.

drugs, which have been summarized as the very important pharmacogenetic (VIP) genes in the Pharmacogenomics Knowledgebase. The expression level of the VIP genes was shown in Figure 2B. We found four VIP genes (CYP3A5, CFTR, CYP2C9, GSTP1) were significantly up-regulated in the SFTC group. Thus, our study was focused on these four differentially expressed VIP genes (VIPDEGs).

Twelve SNPs of four VIPDEGs were included in this study

The SNPs of VIPDEGs were screened from the EXON chip and the CYP3A5 rs776746 genotype was selected from the DMET chip. MAF and HWE of each SNP in donors were calculated, respectively. The genetic variants with a minor allele frequency (MAF) of more than 0.05 were included in the study because of the small sample size. At last, twelve SNPs of VIPDEGs were included in this study (Table 2). Allele frequencies were all in Hardy–Weinberg equilibrium (p > 0.05).

The association between the donor VIPDEGs gene polymorphisms and SFTC

The correlation between SFTC and donor SNP was calculated using PLINK (Table 3). Among the twelve SNPs, three SNPs of CYP3A5 were shown statistical significance. They were rs4646450 (OR=3.23 [1.22-8.60] per each A allele, p = 0.01), rs6977165 (OR=6.44 [1.09-37.87] per each C allele, p = 0.02), rs776746 (OR=3.31 [1.25-8.81] per each A allele, p = 0.01), respectively. However, the other SNPs were not found to be related to SFTC (p > 0.05).

Influence of donor VIPDEGs gene polymorphisms on tacrolimus pharmacokinetics

To understand the mechanism underlying the SFTC. The affections of VIPDEGs gene polymorphisms on tacrolimus metabolism were further investigated. The influence of twelve SNPs genotypes of four VIPDEGs on tacrolimus logCDR at different times after LT was individually analyzed using PLINK (Table 4). Our results revealed three SNPs that showed significant association with SFTC were predictors of tacrolimus logCDR at every week (all p < 0.05).

Besides, different genotype groups based on whether carrying the SFTC-related allele were compared. In CYP3A5 rs4646450 carriers, the tacrolimus logCDR was lower in the A/A or A/G group than that of the G/G group each week (p < 0.05) (Figure 2C). As for CYP3A5 rs6977165, the C/T group was significantly lower than that of the T/T group at each week (p < 0.05) (Figure 2D). And in the A/A or A/G group of CYP3A5 rs776746, tacrolimus logCDR was lower than that of the G/G group at weeks 1, 3 and 4, respectively (p < 0.05) (Figure 2E).

Discussion

In this study, we found that SFTC increased the incidence of IR and dyslipidemia. Besides, rs4646450, rs6977165, and rs776746 in CYP3A5 were associated with SFTC, the reason might be that rs4646450, rs6977165, and rs776746 were correlated with tacrolimus pharmacokinetics.

Most liver transplant recipients receive either tacrolimus or cyclosporine to prevent rejection, while tacrolimus is the first line in immunosuppressive regimens (11). Tacrolimus has a better immunosuppressive effect and fewer side effects as compared to cyclosporine. The conversion from cyclosporine to tacrolimus has been correlated with tacrolimus pharmacokinetics.

In this study, we found that SFTC increased the incidence of IR and dyslipidemia. Besides, rs4646450, rs6977165, and rs776746 in CYP3A5 were associated with SFTC, the reason might be that rs4646450, rs6977165, and rs776746 were correlated with tacrolimus pharmacokinetics.

Most liver transplant recipients receive either tacrolimus or cyclosporine to prevent rejection, while tacrolimus is the first line in immunosuppressive regimens (11). Tacrolimus has a better immunosuppressive effect and fewer side effects as compared to cyclosporine (12–14). A TMC randomized controlled trial suggested that tacrolimus-based immunosuppression is preferable to cyclosporine during the first year after LT (15). And the conversion from cyclosporine to tacrolimus has been reported to improve the cardiovascular risk profile and may retard further decline of renal function after LT (16). However, some LT recipients had to change the immunosuppressive agents from tacrolimus to cyclosporine because of rapid tacrolimus metabolism or diabetes (17–18). Previous studies have shown that this kind of conversion can release adverse reactions in patients to some extent with no increased risk of rejection (19–20), which is also found in our study, but we found SFTC increased the incidence of IR and dyslipidemia. Importantly, patients with SFTC also indicate a low dose of tacrolimus at the initial dose, which is prone to acute rejection. Hence it makes...
sense to know whether LT recipients were suitable for using FK506 at the beginning.

In our study, patients with unstable tacrolimus blood concentration and hyperglycemia were converted to cyclosporine, and these patients were thought to be intolerant to tacrolimus. To better understand the mechanism of tacrolimus intolerance, transcriptome data analysis was performed to identify an expression profile of the very important pharmacogenetic genes between the SFTC group and NSFTC group. Four VIP genes (CYP3A5, CFTR, CYP2C9, GSTP1) were found to be up-regulated in the SFTC. The influence of gene polymorphisms of these four genes on

![FIGURE 1](image)

Switching from FK506 to cyclosporine (SFTC) associated with the poor prognosis. (A) SFTC increased the incidence of insulin resistance; (B) SFTC might increased the incidence of dyslipidemia; (C) SFTC might increased the incidence of hypertension; (D) SFTC might increased the incidence of acute rejection; (E) The forest plot showed the correlation of SFTC and complications. P less than 0.05 means statistical significance.
the SFTC and tacrolimus metabolism were then investigated. Three SNPs (rs4646450, rs6977165, rs776746) of CYP3A5 were found to be the potential risk factors of SFTC. To further investigate the potential mechanism, we further explored the relationship between these SNPs and tacrolimus metabolism at different time points after LT. The results showed that the three SNPs related to SFTC had a statistically significant association with the tacrolimus logCDR every week after LT. When grouping by different genotypes, it was found that individuals carrying the SFTC-related allele had lower logCDR values than those not carrying it. These results suggest that rs4646450, rs6977165, and rs776746 were the independent risk factor of tacrolimus intolerance through the influence of tacrolimus metabolism. To the best of our knowledge, this is the first time to explore the potential factors of tacrolimus intolerance after LT.
**TABLE 2** SNPs of VIPDEGs included in the study.

| SNP          | Gene     | CHR | A1 | A2 | MAF   | HWE (P) |
|--------------|----------|-----|----|----|-------|---------|
| rs28365085   | CYP3A5   | 7   | G  | A  | 1.75% | 1.00    |
| rs55965422   | CYP3A5   | 7   | G  | A  | 0.88% | 1.00    |
| rs4646450    | CYP3A5   | 7   | A  | G  | 30.09%| 0.38    |
| rs6977165    | CYP3A5   | 7   | C  | T  | 2.63% | 1.00    |
| rs776746     | CYP3A5   | 7   | A  | G  | 29.63%| 0.50    |
| rs1800073    | CFTR     | 7   | T  | C  | 0.88% | 1.00    |
| rs141723617  | CFTR     | 7   | C  | T  | 1.32% | 1.00    |
| rs121909046  | CFTR     | 7   | G  | A  | 1.75% | 1.00    |
| rs213950     | CFTR     | 7   | A  | G  | 39.47%| 0.05    |
| rs75789129   | CFTR     | 7   | G  | A  | 5.26% | 1.00    |
| rs1057910    | CYP2C9   | 10  | C  | A  | 3.51% | 1.00    |
| rs1695       | GSTP1    | 11  | G  | A  | 20.18%| 0.39    |

SNP, single-nucleotide polymorphisms; CHR, chromosome number; A1, minor allele code; A2, major allele code; MAF, minor allele frequency; HWE, Hardy–Weinberg Equilibrium; CYP3A5 means cytochrome P450 3A5; CFTR means CF Transmembrane Conductance Regulator; CYP2C9 means Cytochrome P450 family 2 subfamily C member 9; GSTP1 means Glutathione S-Transferase Pi 1; P less than 0.05 means statistical significance.

**TABLE 3** Comparison of genotype distribution between SFTC and NSFTC groups.

| SNP          | Gene     | Genotype frequency, n | P     | OR (95% CI) |
|--------------|----------|-----------------------|-------|-------------|
| rs28365085   | CYP3A5   | GG GA AA              | 0.20  | 4.06(0.40-41.16) |
|              |          | SFTC                  | 0     | 1           |
|              |          | NSFTC                 | 0     | 3           |
|              |          |                        |       | 102         |
| rs55965422   | CYP3A5   | GG GA AA              | 0.68  | 0           |
|              |          | SFTC                  | 0     | 0           |
|              |          | NSFTC                 | 0     | 2           |
|              |          |                        |       | 103         |
| rs4646450    | CYP3A5   | AA AG GG              | 0.01  | 3.23(1.22-8.60) |
|              |          | SFTC                  | 2     | 6           |
|              |          | NSFTC                 | 6     | 46          |
|              |          |                        |       | 52          |
| rs6977165    | CYP3A5   | CC CT TT              | 0.02  | 6.44(1.09-37.87) |
|              |          | SFTC                  | 0     | 2           |
|              |          | NSFTC                 | 0     | 4           |
|              |          |                        |       | 101         |
| rs776746     | CYP3A5   | AA AG GG              | 0.01  | 3.31(1.25-8.81) |
|              |          | SFTC                  | 2     | 6           |
|              |          | NSFTC                 | 6     | 45          |
|              |          |                        |       | 53          |
| rs1800073    | CFTR     | TT TC CC              | 0.68  | 0           |
|              |          | SFTC                  | 0     | 0           |
|              |          | NSFTC                 | 0     | 2           |
|              |          |                        |       | 103         |
| rs141723617  | CFTR     | OC CT TT              | 0.61  | 0           |
|              |          | SFTC                  | 0     | 0           |
|              |          | NSFTC                 | 0     | 3           |
|              |          |                        |       | 102         |
| rs121909046  | CFTR     | GG GA AA              | 0.55  | 0           |
|              |          | SFTC                  | 0     | 0           |
|              |          | NSFTC                 | 0     | 4           |
|              |          |                        |       | 101         |
| rs213950     | CFTR     | AA AG GG              | 0.34  | 1.59(0.61-4.18) |
|              |          | SFTC                  | 3     | 3           |
|              |          | NSFTC                 | 20    | 41          |
|              |          |                        |       | 44          |

(Continued)
Cardiovascular disease, a contributor to the elevated mortality rate among liver transplant recipients, is an adverse consequence of metabolic syndrome (visceral obesity, dyslipidemia, hyperglycemia, and hypertension).\(^{21,22}\) In our study, SFTC increases the incidence of dyslipidemia after LT, which is consistent with the previous studies that tacrolimus appears less likely to cause hypercholesterolemia than cyclosporine\(^{23,24}\). Although a direct correlation between SFTC and new-onset diabetes was not observed, SFTC was associated with insulin resistance appearing in the fourth week after LT; the latter was a potential risk factor for new-onset diabetes.

### TABLE 3

| SNP         | Gene   | Genotype frequency, n | P   | OR (95% CI) |
|-------------|--------|-----------------------|-----|-------------|
| rs75789129  | CFTR   | GG GA AA              | 0.30| 0           |
|             | SFTC   | 0 0 9                 |     |             |
|             | NSFTC  | 0 12 93               |     |             |
| rs1057910   | CYP2C9 | CC CA AA              | 0.62| 1.71(0.20-14.69) |
|             | SFTC   | 0 1 8                 |     |             |
|             | NSFTC  | 0 7 98                |     |             |
| rs1695      | GSTP1  | GG GA AA              | 0.82| 1.14(0.36-3.65) |
|             | SFTC   | 0 4 5                 |     |             |
|             | NSFTC  | 6 30 69               |     |             |

OR, estimated odds ratio (for A1); CI, confidence interval; CYP3A5 means cytochrome P450 3A5; CFTR means CF Transmembrane Conductance Regulator; CYP2C9 means Cytochrome P450 family 2 subfamily C member 9; GSTP1 means Glutathione S-Transferase Pi 1; P less than 0.05 means statistical significance.

### TABLE 4

| SNP          | Gene   | Genotype (Frequency,n) | 1st | 2nd | 3rd | 4th |
|--------------|--------|------------------------|-----|-----|-----|-----|
| rs28365085   | CYP3A5 | GG GA AA               | 0.02| 0.41| 0.11| 0.07|
|              |        | 0 4 110                |     |     |     |     |
| rs55965422   | CYP3A5 | GG GA AA               | 0.42| 0.86| 0.74| 0.69|
|              |        | 0 2 112                |     |     |     |     |
| rs4646450    | CYP3A5 | AA AG GG               | <0.001| 0.03| 0.02| <0.001|
|              |        | 8 52 53                |     |     |     |     |
| rs6977165    | CYP3A5 | CC CT TT               | 0.00| 0.02| 0.01| 0.049|
|              |        | 0 6 108                |     |     |     |     |
| rs776746     | CYP3A5 | AA AG GG               | <0.001| 0.05| 0.02| <0.001|
|              |        | 8 51 54                |     |     |     |     |
| rs1800073    | CFTR   | TT TC CC               | 0.13| 0.08| 0.04| 0.53|
|              |        | 0 2 112                |     |     |     |     |
| rs141723617  | CFTR   | CC CT TT               | 0.17| 0.71| 0.86| 0.46|
|              |        | 0 3 111                |     |     |     |     |
| rs121909046  | CFTR   | GG GA AA               | 0.09| 0.80| 0.96| 0.63|
|              |        | 0 4 110                |     |     |     |     |
| rs213950     | CFTR   | AA AG GG               | 0.05| 0.19| 0.01| 0.09|
|              |        | 23 44 47               |     |     |     |     |
| rs75789129   | CFTR   | GG GA AA               | 0.75| 0.69| 0.47| 0.26|
|              |        | 0 12 102               |     |     |     |     |
| rs1057910    | CYP2C9 | CC CA AA               | 0.77| 0.78| 0.03| 0.10|
|              |        | 0 8 106                |     |     |     |     |
| rs1695       | GSTP1  | GG GA AA               | 0.72| 0.34| 0.76| 0.87|
|              |        | 6 34 74                |     |     |     |     |

CYP3A5 means cytochrome P450 3A5; CFTR means CF Transmembrane Conductance Regulator; CYP2C9 means Cytochrome P450 family 2 subfamily C member 9; GSTP1 means Glutathione S-Transferase Pi 1; P less than 0.05 means statistical significance.
drugs in various human organs and tissues, especially in the liver (25, 26) CYP3A5, encoding the cytochrome P450 (CYP) enzymes 3A5, is the most influential gene in tacrolimus pharmacokinetics by far (27) and CYP3A5 rs776746 polymorphism is the most well-known found to be related to tacrolimus pharmacokinetics. Patients can be divided into CYP3A5 expressers carrying at least one CYP3A5*1 allele and CYP3A5 non-expressers with CYP3A5*3/*3 genotype based on the CYP3A5 rs776746 genotype (28). And the former requires a higher maintenance tacrolimus dose to achieve the target tacrolimus concentration as compared to the latter (29), which is also found in our study. As for CYP3A5 rs4646450, there have been several studies that pointed out that it might be associated with tacrolimus metabolism (30, 31). However, there are no previous reports on the effects of CYP3A5 rs6977165 polymorphism on tacrolimus metabolism. In our study, we found that donor rs4646450, donor rs6977165, and donor rs776746 polymorphism were the independent risk factors with an increased risk of >3-fold of tacrolimus intolerance by each risk allele. And all three SNPs showed a significant association with tacrolimus pharmacokinetics in the first four weeks.

Several limitations existed in our study. Firstly, the limitation of the donor demographic data may influence the result because the expression data stemmed from the donor liver samples. But the quality of donors’ livers strictly conformed to the standards of transplantation which in a way offset some of our concerns. Secondly, the result may be controversial because of the small sample size, further study will be needed by using a larger data set. Lastly, we only focus on the donor genotypes in our study since no recipient expression data is available. It is also necessary to apply this workflow to recipient samples in future studies.

In conclusion, this study demonstrated that SFTC is a potential risk factor for dyslipidemia and IR. Besides, donor CYP3A5 rs4646450, CYP3A5 rs6977165, and CYP3A5 rs776746 genotype might relate to tacrolimus intolerance in Chinese liver transplant recipients by affecting tacrolimus metabolism, among which donor rs6977165 is the first time suggested correlated with tacrolimus metabolism. This information may be useful to obtain personalized medicine earlier, avoid the incidence of adverse effects and relieve medical care burdens for LT patients.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ncbi.nlm.nih.gov/, GSE53792.

Ethics statement

The study was approved by the Ethics Committee of Shanghai First Hospital affiliated with Shanghai Jiao Tong University. These methods are based on the Helsinki Declaration and its subsequent amendments or similar ethical standards. The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conceptualization: ZP, JF, and HP. Methodology: YL, RW, and PW. Data collection: JZ, TZ, PZ, and FZ. Visualization: RW, PW, and YL. Funding acquisition: ZP. Writing – original draft: YL, RW, and PW. Writing – review & editing: YL, WA and HW. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the National Natural Science Foundation of China (82070677).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.944442/full#supplementary-material

**SUPPLEMENTARY FIGURE 1**

The influence of SFTC to survival. Kaplan-Meier survival curves analysis of patients between the SFTC and NSFTC groups; SFTC means switching from tacrolimus to cyclosporine; *P* less than 0.05 means statistical significance.

**SUPPLEMENTARY FIGURE 2**

The correlation of complications and survival. (A) Kaplan–Meier survival curves analysis of patients between the rejection and no-rejection groups; (B) Kaplan–Meier survival curves analysis of patients between hypertension and no-hypertension groups; (C) Kaplan–Meier survival curves analysis of patients between IR and no-IR groups; (D) Kaplan–Meier survival curves analysis of patients between dyslipidemia and no-dyslipidemia groups. IR means insulin resistance; *P* less than 0.05 means statistical significance.
References

1. Bhat M, Usmani SE, Athie A, Woo M. Metabolic consequences of solid organ transplantation. Endoc Rev (2021) 42(2):171–97. doi: 10.1210/endrev/bnaa070

2. Meirelles Júnior RE, Salvaglio P, Rezende MB, et al. Liver transplantation: history, outcomes and perspectives. Einstein (Sao Paulo) 13(1):149–52.

3. Bectchi C, Ferrarese A, Zeni N, et al. A prospective longitudinal assessment of de novo metabolic syndrome after liver transplantation. Clin Transplant (2022) 36(2):e14533. doi: 10.1111/ctr.14532

4. Scales JR, Levi ST, Ally W, Brayman KL. Tacrolimus for the prevention and treatment of rejection of solid organ transplants. Expert Rev Clin Immunol (2016) 12(3):333–42. doi: 10.14885/1744666x.2016.1132093

5. Plosker GL, Foster RH. Tacrolimus. Drugs (2000) 59(2):323–89. doi: 10.2165/00003495-20005902-00021

6. Coste G, Lemaître F. The role of intra-patient variability of tacrolimus drug concentrations in solid organ transplantation: A focus on liver, heart, lung and pancreas. Pharmaceutics (2022) 14(2). doi: 10.3390/pharmaceutics14020379

7. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA (2001) 285(19):2486–97.

8. Wang X, Tang H, Teng M, et al. Mapping of hepatic expression quantitative trait loci (eQTLs) in a Han Chinese population. J Med Genet (2014) 51(5):319–26. doi: 10.1136/jmedgenet-2013-102045

9. Liu Y, Zhang T, Li C, et al. SLC28A3 rs7853758 as a new biomarker of tacrolimus elimination and new-onset hypertension in Chinese liver transplantation patients. Drug Metab Dispos (2017) 45(11):1688–92. doi: 10.1124/dmd.117.079309

10. Lazzaro C, McKechne C, McKenna M. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analysis. J Nephrol (2015) 28(5):580–8.

11. Liu XY, Yu LX, Fu SJ, et al. [Application of tacrolimus and cyclosporine in HBV-carrying renal transplant recipients]. Nan Fang Yi Ke Da Xue Xue Bao (2007) 27(7):1090–2.

12. O’Grady JG, Burroughs A, Hardy P, Elbourne D, Truandale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet (2002) 360(9340):1119–25. doi: 10.1016/S0140-6736(02)11966-2

13. Beckbein S, Klein C, Varghese J, et al. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Aliment Pharmacol Ther (2009) 30(8):834–42. doi: 10.1111/j.1365-2036.2009.04099.x

14. Aboulosoud MS, Kumar MS, Brayman KL, Emre S, Bynon JS. Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant (2002) 16(3):168–72. doi: 10.1034/j.1399-0911.2002.01054.x

15. Ogino S, Hashikura Y, Katsuyama Y, et al. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients. Transplant Proc (2004) 36(2 Suppl):299s–301s. doi: 10.1016/j.transproceed.2003.12.037

16. Tamura S, Sugawara Y, Kishi Y, et al. Conversion to cyclosporine provides valuable rescue therapy for living donor adult liver transplant patients intolerant to tacrolimus: A single-center experience at the university of Tokyo. Transplant Proc (2004) 36(10):3242–4. doi: 10.1016/j.transproceed.2004.11.096

17. Emre S, Genyk Y, Schluger LK, et al. Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. Transplant Int (2000) 13(1):73–8. doi: 10.1111/j.1398-2277.2000.tb01490.x

18. Thoefner LB, Rostved AA, Pommergau HC, Rasmussen A. Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando) (2018) 32(1):69–77. doi: 10.1016/j.trre.2017.03.004

19. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet (London Engl) (2001) 359(9351):95–9. doi: 10.1053/ljmt.2001.24637

20. Pratschke J, Neuhaus R, Tullius SG, et al. Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. Transplantation (1997) 64(6):934–40. doi: 10.1097/00007890-199709270-00029

21. Staete CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet (2010) 49(3):141–75. doi: 10.2165/1137350-000000000-00000

22. Xiang Q, Wu W, Zhao N, et al. The influence of genetic polymorphisms in drug metabolism enzymes and transporters on the pharmacokinetics of different fluorastatin formulations. Asian J Pharm Sci (2020) 15(2):264–72. doi: 10.1016/j.ajps.2019.06.002

23. Lee DH, Lee H, Yoon HY, Jee J, Gwak HS. Association of P450 oxidoreductase gene polymorphism with tacrolimus pharmacokinetics in renal transplant recipients: A systematic review and meta-analysis. Pharmacovigilance (2022) 14(2). doi: 10.3390/pharmaceutics14020261

24. Xie HG, Wood AJ, Kim RR, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics (2004) 5(3):243–72. doi: 10.1517/phj.5.3.243.29833

25. Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement. Transplantation (2002) 74(11):1486–9. doi: 10.1097/00007890-200212150-00002

26. Onizuka M, Kunii N, Toyosaki M, et al. Cytochrome CYP450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients. Bone Marrow Transplant (2011) 48(8):1113–7. doi: 10.1038/bmt.2010.273

27. Liu J, Ouyang Y, Chen D, et al. Donor and recipient P450 gene polymorphisms influence individual pharmacological effects of tacrolimus in Chinese liver transplantation patients. Int Immunopharmacol (2018) 57:18–24. doi: 10.1016/j.intimp.2018.02.003